主要文件

查看所有文档

Y0001015

诺氟沙星

Name: 诺氟沙星
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

1-乙基-6-氟-1,4-二氢-4-氧代-7-(1-哌嗪基)-3-喹啉羧酸, 1-乙基-6-氟-1,4-二氢-4-氧代-7-哌嗪-3-喹啉羧酸

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₆H₁₈FN₃O₃

化学文摘社编号:

70458-96-7

分子量:

319.33

NACRES:

NA.24

PubChem Substance ID:

329831219

UNSPSC Code:

41116107

MDL number:

MFCD00079532

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

norfloxacin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCN1C=C(C(O)=O)C(=O)c2cc(F)c(cc12)N3CCNCC3

InChI

1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)

InChI key

OGJPXUAPXNRGGI-UHFFFAOYSA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Norfloxacin for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

诺氟沙星通过干扰 ATP 诱导转换 DNA 与 DNA 旋转酶（拓扑异构酶）复合物的结构转换而阻断 DNA 复制。
操作方式：抑制细菌 DNA 复制
抗菌谱：革兰氏阴性菌；对革兰氏阳性菌效果较差

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

In vitro antimicrobial activity of hydroxypyridinone hexadentate-based dendrimeric chelators alone and in combination with norfloxacin.

Ying-Jun Zhou et al.

FEMS microbiology letters, 355(2), 124-130 (2014-05-13)

The antimicrobial activity of one 3-hydroxypyridin-4-one (HPO) hexadentate (1) and three HPO hexadentate-based dendrimeric chelators (2-4) was evaluated. They were found to exhibit marked inhibitory effect on the growth of two Gram-positive bacteria and two Gram-negative bacteria. The combination treatment

Review of norfloxacin in lower urinary tract infections.

L Miano et al.

European urology, 17 Suppl 1, 13-18 (1990-01-01)

A review of worldwide clinical trials with norfloxacin in the treatment of uncomplicated urinary tract infections (UTIs), as well as our personal experience with 215 assessable patients, is presented. Almost all patients received 400 mg b.i.d. for 3-15 days. Bacteriological

Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects.

D R Nalin

European journal of cancer & clinical oncology, 24 Suppl 1, S55-S61 (1988-01-01)

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0001015	04061833805633